QuatRx Announces Further Positive Phase 3 Results for Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena™ (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3 studies. QuatRx intends to use these results in support of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2010 seeking approval for Ophena™, a new SERM (selective estrogen receptor modulator) for the treatment...

Want to see the full article?

• Purchase this article for only $3.00